Specialty Active Pharmaceutical Ingredients Market

Specialty Active Pharmaceutical Ingredients (API) Market: Cost-effective Manufacturing Practices by Contract Manufacturing Organizations to Drive the Market Growth: Global Industry Analysis and Opportunity Assessment, 2016 - 2024

Ask The Analyst Customization Available Request Methodology

Introduction

Over the last few years, manufacturing of specialty active pharmaceutical ingredients in contract manufacturing organizations (CMOs) is increasing at a rapid pace. In order to reduce operational costs, pharmaceutical companies in the health care industry are utilizing CMO services to develop active pharmaceutical ingredients. Thus, companies are developing finished pharmaceutical products (FPP) such as tablets, capsules and syrups etc. In order to meet customer needs, specialty active pharmaceutical ingredient manufacturers are entering into various manufacturing agreements with pharmaceutical companies. Moreover, agreements between specialty pharmaceutical ingredient manufactures for production of specialty active pharmaceutical ingredients is also expected to fuel market growth in terms of revenue over the forecast period. Furthermore, CMOs are providing robust manufacturing facilities with GMP and EU certificates to develop specialty active pharmaceutical ingredients. Furthermore, large market players in the pharmaceutical industry are currently following a backward integration strategy to manufacture active pharmaceutical ingredients to generate more revenue.

Market Value and Forecast

The global specialty active pharmaceutical ingredients (API) market is anticipated to record a year-over-year growth rate of 7.9% and reach a market value of US$ 119,513.1 Mn in 2016.

Market Dynamics

Patent expiration is the key factor driving overall growth of the generic drugs market. Thus, increasing generic drugs is expected to fuel production of specialty active pharmaceutical ingredients. Moreover, prevalence rate of various chronic disease such as cardiovascular, cancer and infectious diseases is expected to drive production volumes of specialty active pharmaceutical ingredients over 2016–2024.

Market Segmentation, by Product Type

By product type, FMI has segmented the market into steroidal API, peptides, carbohydrate API, small molecule and high potency API. Among all products, small molecule segment accounted for largest market share in 2015 and the trend is projected to continue over the forecast period, with highest CAGR of over 8%. Small molecule segment revenue share is expected to high owing to increasing generic drugs in the pharmaceutical product segment. Peptide and carbohydrate are most lucrative segments after the small molecule segment.

specialty active pharmaceutical ingredients market

Market Segmentation, by Consumption

By consumption, the market has been segmented into in-house and outsourced. Outsourced segment is estimated to account for large market share in 2016 and the trend is expected to continue over the forecast period. Outsourcing segment revenue is expected to expand at a CAGR of over 10% during the forecast period, owing to increasing production of generic drugs and increasing prevalence of chronic diseases such as cancer, cardiovascular and diabetes.

Key Regions

North America market revenue is expected to expand at the highest CAGR over the forecast period. Increasing number of CMOs along with increasing production of generic drugs are factors expected to drive revenue growth of the overall specialty active pharmaceutical ingredient market in the region. As per FMI market analysis, the market in the U.S. is expected to register at a CAGR of over 8% during the forecast period due to robust manufacturing facilities and increasing government investments on development of new drugs in the country. The number of companies manufacturing active pharmaceutical ingredients in North America is relatively high when compared to other regions. Moreover, companies are entering into strategic agreements to increase production volumes of active pharmaceutical ingredients. This in turn is expected to drive overall revenues from the active pharmaceutical ingredients market in the region. Market in Europe is expected to expand at a moderate growth in a Y-o-Y over the forecast period.

The Asia Pacific market is expected to expand at the highest CAGR in revenue terms, followed by Latin America and Middle East & Africa over the forecast period.

Key Players

Some key market participants included in FMI’s global specialty API market report include Johnson Matthey, Siegfried, Almac, PolyPeptide Laboratories, AmbioPharm, Inc., Corden Pharma, Pepscan, BCN peptide, Provence Technologies Groups, SennChemicals AG, Avecia OligoMedicines, Santaris Pharma, ST Pharm Oligo Center, Cepia Sanofi, Biospring, Pfizer CenterSource, Symbiotec Pharma Lab Pvt. Ltd., Gadea Grupo Farmacéutico, STEROID S.p.A., Dolder AG , Dalton Pharma Services, FarmaBios Spa, Dextra Laboratories Limited, GlycoSyn, Inalco Pharma, Sussex Research, Pfanstiehl, Inc., Noramco, Inc., Ash Stevens Fermion (public) Olon SpA and others.

Future Market Insights offers a 10-year forecast on the global specialty active pharmaceutical ingredient market between 2016 and 2026. In terms of value, the specialty active pharmaceutical ingredient market is expected to register a CAGR of 7.9% during the forecast period. This study demonstrates market dynamics and trends in major countries that are expected to influence the current environment and future status of the global specialty active pharmaceutical ingredient market over the forecast period.

The global specialty active pharmaceutical ingredients market report provides analysis and insights on active pharmaceutical ingredients, which are biologically active chemicals used as intermediate components in pharmaceutical manufacturing such as tablets, capsules, syrups etc.,

To understand and assess various opportunities in this market, the report is categorically split into three sections, namely market analysis by product type, consumption and region. The report analyzes the global specialty active pharmaceutical ingredient market in terms of value (US$ Mn).

The report starts with an overview of the global specialty active pharmaceutical ingredient market. In the same section, FMI covers the global specialty active pharmaceutical ingredient market performance in terms of value. This section also includes FMI’s analysis of key trends, drivers, and restraints from supply and demand perspectives. The report also cover the opportunities in the global specialty active pharmaceutical ingredient market.

The next section of the report analyzes the market on the basis of product type and presents the forecast in terms of value for all years till 2024. On the basis of product type, the market has been segmented as follows:

  • Steroidal API
  • Peptide API
  • Carbohydrate API
  • Small Molecule API
  • High Potency API

The next section of the report analyzes the market on the basis of consumption segment and presents forecast in terms of value for all years till 2024. Consumption segments covered in the report are as follows:

  • In-house
  • Outsourced

The next section analyzes the market on the basis of regions in terms of value for the forecast period. Regions covered in the report are as follows:

  • North America
  • Europe
  • Rest of the World

To reach market size, the report considers market value of the global specialty active pharmaceutical ingredients across the above-mentioned regions. The market estimation presented in the report evaluates the total revenue generated in the global specialty active pharmaceutical ingredient market over the forecast period. When developing the market forecast, the starting point involves sizing up the current market, which forms the basis of the forecast on how the market is anticipated to take shape in the near future. For this, FMI conducted interviews with several subject matter experts in the specialty active pharmaceutical ingredient domain across the globe. Given the characteristics of the market, we triangulated the outcome based on different analysis based on supply side, demand side and dynamics of the market. In this report, quantification of data has been conducted along with provision of quality insights collected directly from the market through discussion with suppliers, distributors and subject-matter experts.

We have also taken into consideration the year-on-year growth of the global specialty active pharmaceutical ingredient market, based on regional growth analysis, to understand the predictability of the market and to identify the right opportunities in it.

As previously highlighted, the market for global specialty active pharmaceutical ingredient is split into various segments on the basis of product type, consumption and region. All segments have been analyzed in terms of Basis Point Share (BPS) to understand individual segment’s relative contribution to market growth. This detailed level of information is important for identification of various key trends in the global specialty active pharmaceutical ingredient market.

Another key feature of this report is the analysis of the global specialty active pharmaceutical ingredient market, by region, which is further segmented on the basis of countries and revenue forecast in terms of absolute dollar (US$) opportunity. Regional trends have been introspected, identified and applied while forecasting the growth rates of the market. Additionally, the absolute dollar opportunity provided in the report is critical in assessing the level of opportunity that a provider can look to achieve from a sales perspective in the global specialty active pharmaceutical ingredient market. 

In this report, FMI has also developed a market attractiveness index for all three segments, namely product type, consumption and regional segments. This index is intended to help in identifying real opportunities in the market.

In the final section of the report, the global specialty active pharmaceutical ingredient market landscape is included to provide report audiences with a dashboard view, based on categories of providers in the global personal emergency response systems product portfolio; their key developments and strategies have also been included wherever possible. 

Some key market participants included in FMI’s global specialty API market report include Johnson Matthey, Siegfried, Almac, PolyPeptide Laboratories, AmbioPharm, Inc., Corden Pharma, Pepscan, BCN peptide, Provence Technologies Groups, SennChemicals AG, Avecia OligoMedicines, Santaris Pharma , ST Pharm Oligo Center, Cepia Sanofi, Biospring, Pfizer CenterSource, Symbiotec Pharma Lab Pvt. Ltd., Gadea Grupo Farmacéutico, STEROID S.p.A., Dolder AG , Dalton Pharma Services, FarmaBios Spa, Dextra Laboratories Limited, GlycoSyn, Inalco Pharma, Sussex Research, Pfanstiehl, Inc., Noramco, Inc., Ash Stevens Fermion (public) Olon SpA and others.

Specialty Active Pharmaceutical Ingredients Market Reports - Table of Contents

1. Preface

1.1. Report Description

1.2. Research Methodology

1.3. Market Segmentation

1.4. Assumptions

2. Executive Summary

2.1. Global Specialty Active Pharmaceutical Ingredients (API) Market: Market Snapshot 

2.2. Global Specialty Active Pharmaceutical Ingredients (API) Market Revenue, 2014-2024 (US$ Mn) and Year-on-Year Growth (%) 

3. Market Definition

4. Oligonucleotide Drug Pipeline Analysis (miRNA, siRNA and RNAi Drugs)

5. Global Therapeutic Drugs Market, by Type of API, 2014-2024 (US$ Mn)

5.1. Overview

5.2. Small Molecules

5.2.1. Controlled Substances

5.2.2. HPAPI

5.3. Peptides & Oligonucleotides

5.4. Carbohydrate Drugs

5.5. Steroidal Drugs

5.6. Market Dynamics

5.6.1. Macro-economic Factors

5.6.2. Drivers

5.6.2.1. Supply Side

5.6.2.2. Demand Side

5.6.3. Restraints

5.6.4. Opportunity

5.6.5. Forecast Factors – Relevance and Impact

6. Global Specialty Active Pharmaceutical Ingredients Market Revenue, by Consumption, 2014–2024

6.1. Overview

6.2. Small Molecules

6.2.1. In-house

6.2.2. Outsourced

6.3. Peptides

6.3.1. In-house

6.3.2. Outsourced

6.4. Oligonucleotides

6.4.1. In-house

6.4.2. Outsourced

6.5. Carbohydrate Drugs

6.5.1. In-house

6.5.2. Outsourced

6.6. Steroidal Drugs

6.6.1. In-house

6.6.2. Outsourced

6.7. Controlled Substance

6.7.1. In-house

6.7.2. Outsourced

6.8. HPAPI

6.8.1. In-house

6.8.2. Outsourced

7. Global Specialty Active Pharmaceutical Ingredients Sub-Segment Market Revenue, by Product Type, 2014–2024

7.1. Global Small Molecules API Market Revenue, by Type of API, 2014-2024 (US$ Mn)

7.1.1. Overview

7.2. Global Peptide API Market Revenue, by Type of Synthesis, 2014-2024 (US$ Mn)

7.2.1. Overview

7.3. Global Carbohydrate API Market Revenue, by Type of Drugs, 2014-2024 (US$ Mn)

7.3.1. Carbohydrate Drugs

7.3.2. Carbohydrate-based Drugs

7.3.3. Glycoprotein Drugs

7.4. Global Steroidal API Market Revenue, by Type of Drugs, 2014-2024 (US$ Mn)

7.4.1. Corticosteroids

7.4.2. Sex Hormones

7.5. Global Controlled Substance API Market Revenue, by Type of Drugs, 2014-2024 (US$ Mn)

7.5.1. Synthetic Derivatives

7.5.2. Natural Derivatives

8. North America API Market Revenue, 2014-2024 (US$ Mn)

8.1. North America API Market Revenue, by Type of API, 2014-2024 (US$ Mn)

8.1.1. Overview

8.1.1.1. Small Molecules

8.1.1.2. Peptides

8.1.1.3. Oligonucleotides

8.1.1.4. Carbohydrate Drugs

8.1.1.5. Steroidal Drugs

8.1.1.6. Controlled Substances

8.2. Europe API Market Revenue, by Type of API, 2014-2024 (US$ Mn)

8.2.1. Overview

8.2.1.1. Small Molecules

8.2.1.2. Peptides

8.2.1.3. Oligonucleotides

8.2.1.4. Carbohydrate Drugs

8.2.1.5. Steroidal Drugs

8.2.1.6. Controlled Substances

8.3. Rest of the World API Market Revenue, 2014-2024 (US$ Mn)

8.3.1. Overview

8.3.1.1. Small Molecules

8.3.1.2. Peptides

8.3.1.3. Oligonucleotides

8.3.1.4. Carbohydrate Drugs

8.3.1.5. Steroidal Drugs

8.3.1.6. Controlled Substances

9. Company Profile

9.1. Company Details (HQ, Foundation Year, Employee number, Strength)

9.2. Market Presence, By Segment and Geography

9.3. Key Developments

9.4. Strategy and Historical Roadmap

9.5. Revenue and Operating Profits (Best Effort Basis for Private Companies)

9.6. Plant Location

9.7. Key Executive

9.8. Small Molecule API CDMO

9.8.1. Johnson Matthey

9.8.2. Siegfried

9.8.3. Almac

9.9. Peptide API

9.9.1. PolyPeptide Laboratories

9.9.2. AmbioPharm, Inc.

9.9.3. Corden Pharma

9.9.4. Pepscan

9.9.5. BCN peptide

9.9.6. Provence Technologies Groups

9.9.7. SennChemicals AG

9.10. Oligonucleotide API

9.10.1. Avecia OligoMedicines 

9.10.2. Santaris Pharma  - acquired by Roche in 2014 

9.10.3. ST Pharm Oligo Center 

9.10.4. Cepia Sanofi 

9.10.5. Biospring

9.11. Steroid API

9.11.1. Pfizer CenterSource

9.11.2. Symbiotec Pharma Lab Pvt. Ltd. 

9.11.3. Gadea Grupo Farmacéutico

9.11.4. STEROID S.p.A. 

9.11.5. Dolder AG 

9.11.6. Dalton Pharma Services

9.11.7. FarmaBios Spa

9.12. Carbohydrate API

9.12.1. Dextra Laboratories Limited

9.12.2. GlycoSyn 

9.12.3. Inalco Pharma

9.12.4. Sussex Research

9.12.5. Pfanstiehl, Inc. 

9.13. Controlled Substance

9.13.1. Noramco, Inc.

9.13.2. Johnson Matthey

9.13.3. Siegfried

9.13.4. Rhodes Technologies

9.14. HPAPI

9.14.1. Ash Stevens

9.14.2. Fermion (public)

9.14.3. FARMHISPANIA GROUP

9.14.4. Olon SpA

Specialty Active Pharmaceutical Ingredients Market Reports - List of Tables

Table 01: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn), by Product Type, 2014–2024

Table 02: Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn), by In-house Consumption Segment, 2014–2024

Table 03: Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn), by Outsourced Consumption Segment, 2014–2024

Table 04: Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn), by Product Type Sub-Segment, 2014–2024

Table 05: North America Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn), by Product Type, 2014–2024

Table 06: Europe Specialty Active Pharmaceutical Ingredients Market Value (US$), by Product Type, 2014–2024

Table 07: Rest of World Specialty Active Pharmaceutical Ingredients Market Value, by Product Type, US$ Mn, 2014–2024

Specialty Active Pharmaceutical Ingredients Market Reports - List of Figures

 

Figure 02: Peptide Drug Pipeline Analysis by Developmental Phase, 2016

Figure 03: Peptide Drug Pipeline Analysis by Companies, 2016

Figure 04: Steroidal Drug Pipeline Analysis by Developmental Phase, 2016

Figure 05: Steroidal Drug Pipeline Analysis by Companies, 2016

Figure 06: High Potency Drug Pipeline Analysis by Developmental Phase, 2016

Figure 07: High Potency Drug Pipeline Analysis by Companies, 2016

Figure 08: Specialty Active Pharmaceutical Ingredient Market Value Share & BPS Analysis, by Product Type, 2015 & 2024

Figure 09: Specialty Active Pharmaceutical Ingredient Market Y-o-Y Growth Comparison, by Product Type, 2015–2024

Figure 10: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Controlled Substances, 2014–2024

Figure 11: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by High Potency API, 2014–2024

Figure 12: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Peptides Segment, 2014–2024

Figure 13: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Carbohydrate Drugs Segment, 2014–2024

Figure 14: Specialty Active Pharmaceutical Ingredient Market Value Share & BPS Analysis, by Product Type, 2015 & 2024

Figure 15: Specialty Active Pharmaceutical Ingredient Market Y-o-Y Growth Comparison, by Product Type, 2015–2024

Figure 16: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Controlled Substances, 2014–2024

Figure 17: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by High Potency API, 2014–2024

Figure 18: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Peptides Segment, 2014–2024

Figure 19: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Carbohydrate Drugs Segment, 2014–2024

Figure 20: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Steroidal Drugs Segment, 2014–2024

Figure 21: Specialty Active Pharmaceutical Ingredient Market Attractiveness Analysis, by Product Type, 2014–2024

Figure 22: Specialty Active Pharmaceutical Ingredients Market Value Share & BPS Analysis, by Consumption, 2015 & 2024

Figure 23: Specialty Active Pharmaceutical Ingredients Market Y-o-Y Growth Comparison, by Consumption, 2015–2024

Figure 24: Controlled Substance Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by In-house Consumption, 2014–2024

Figure 25: Controlled Substance Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by Outsourced Consumption, 2014–2024

Figure 26: High Potency Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by In-house Consumption, 2014–2024

Figure 27: High Potency Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by Outsourced Consumption, 2014–2024

Figure 28: Peptide Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by In-house Consumption, 2014–2024

Figure 29: Peptide Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by Outsourced Consumption, 2014–2024

Figure 30: Carbohydrate Drugs Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by In-house Consumption, 2014–2024

Figure 31: Carbohydrate Drugs Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by Outsourced Consumption, 2014–2024

Figure 32: Steroidal Drugs Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by In-house Consumption, 2014–2024

Figure 33: Steroidal Drugs Specialty Active Pharmaceutical Ingredients Market Value (US$ Mn) & Y-o-Y Growth (%), by Outsourced Consumption, 2014–2024

Figure 34: Specialty Active Pharmaceutical Ingredients Market Attractiveness Analysis by In-house Consumption, 2016–2024

Figure 35: Specialty Active Pharmaceutical Ingredients Market Attractiveness Analysis by Outsourced Consumption, 2014–2024

Figure 36: Global API Market Value (US$ Mn) & Y-o-Y Growth Forecast, by Small Molecules 2014–2024

Figure 37: Global API Market Value (US$ Mn) & Y-o-Y Growth Forecast, by Peptide, 2014–2024

Figure 38: Carbohydrate Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Carbohydrate Drugs Sub-segment, 2014–2024

Figure 39: Carbohydrate Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Carbohydrate-based Drugs Sub-segment, 2014–2024

Figure 40: Carbohydrate Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Glycoprotein Drugs Sub-segment, 2014–2024

Figure 41: Steroidal Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Corticosteroids Sub-segment, 2014–2024

Figure 42: Steroidal Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Sex Hormones Sub-segment, 2014–2024

Figure 43: Steroidal Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Other Steroidal Drugs Sub-segment, 2014–2024

Figure 44: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Synthetic Controlled Substance Category, 2014–2024

Figure 45: Specialty Active Pharmaceutical Ingredient Market Value (US$ Mn) & Y-o-Y Growth (%), by Natural Controlled Substance Category, 2014–2024

Figure 46: Global API Market Share Analysis (%), by Region, 2014 & 2024

Figure 47: Global API Market Attractiveness Index, by Region, 

Figure 48: North America Specialty Active Pharmaceutical Ingredient value Y–o–Y Growth (%), 2014 – 2022

Figure 49: North America Specialty Active Pharmaceutical Ingredient Market Absolute $ Opportunity (US$ Mn), 2014–2024

Figure 50: Europe Specialty Active Pharmaceutical Ingredient value Y–o–Y Growth (%), 2014–2024

Figure 51: Europe Specialty Active Pharmaceutical Ingredient Market Absolute $ Opportunity (US$ Mn), 2014–2024

Figure 52: Rest of World Specialty Active Pharmaceutical Ingredient value Y–o–Y Growth (%), 2014–2024

Figure 53: Rest of World Specialty Active Pharmaceutical Ingredient Market Absolute $ Opportunity (US$ Mn), 2014–2024